NCT04526730 2026-02-20
Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
Clinical Trials
12 trialsNCT07306273 2025-12-29
IRE Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy
Ruijin Hospital
Phase 2 Recruiting
NCT04760327 2024-10-17
GynECT
Institute of Oncology Ljubljana
Phase 2 Recruiting
NCT03630640 2024-07-31
NIVOLEP
Assistance Publique - Hôpitaux de Paris
Phase 2 Completed
NCT05609656 2024-06-03
ELI
Zealand University Hospital
Phase 2 Terminated
NCT05435053 2023-09-15
CHECKPOINT
Zealand University Hospital
Phase 2 Terminated
NCT03823131 2023-05-09
Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat
University of California, San Francisco
Phase 2 Terminated
NCT02082782 2022-12-20
COLDFIRE-2
Amsterdam UMC, location VUmc
Phase 2 Completed
NCT04835402 2022-03-09
EPIC-1
Aalborg University Hospital
Phase 2 Unknown
NCT01835977 2020-12-16
Multi-Center Randomized Clinical Trial Irreversible Electroporation for the Ablation of Localized Prostate Cancer
Clinical Research Office of the Endourological Society
Phase 2 Unknown
NCT02549742 2017-01-18
Electrochemotherapy on Head and Neck Cancer
Rigshospitalet, Denmark
Phase 2 Unknown
NCT02828709 2016-09-27
Safety and Feasibility of IRE for SRMs
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 2 Unknown